Hogan Lovells 2024 Election Impact and Congressional Outlook Report
J. Nicholas Hoover
Counsel Corporate & Finance
His transactional experience includes equity and debt financings that range from registered offerings – including IPOs, other underwritten offerings, registered direct offerings, and secondary offerings – to private placements of common and preferred equity and convertible and non-convertible notes. He also has experience with mergers and acquisitions and joint ventures.
Nick focuses in particular on helping life sciences companies navigate the unique needs of their industry, while also advising organizations in other fields, including technology, media, education, and aerospace and defense. Nick has worked with NYSE and Nasdaq listed entities ranging from smaller reporting and emerging growth companies to the Fortune 500.
Prior to becoming a lawyer, Nick wrote for an information technology news publication. Nick worked full time as a reporter during law school, receiving the University of Maryland's Larry P. Shoda award for scholastic excellence and special commitment required of evening students. During that time he was also executive articles editor for the Journal of Business and Technology Law.
NextCure, Inc. (Nasdaq: NXTC) on its US$86.25m initial public offering.
Twenty-First Century Fox, Inc. on various debt offerings and corporate governance and disclosure matters.
TESARO, Inc. on follow-on equity offerings, a convertible notes offering, corporate governance and disclosure matters, and its acquisition.
Vaccinex, Inc. on its initial public offering.